Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache related disability. Treatment-related side effects overall did not differ significantly from placebo and discontinuation rate due to side effects has been low across the clinical trials, perhaps in view of their peripheral mode of action. Along with their route and frequency of administration, these novel class of drugs may constitute an improvement compared with the established arsenal of migraine treatments. Erenumab is a fully human antibody and the only mAb acting on the CGRP pathway by blocking its receptor. It is the first of the CGRP mAb class approved by the US Food and Drug Administration (May 2018) and the European Medicines Agency (July 2018). Erenumab exists in two different doses (70 mg and 140 mg) and it is administered with monthly subcutaneous injections. This review summarises erenumab pharmacological characteristics, clinical trials data, focusing on the potential role of this treatment in clinical practice.

降钙素基因相关肽（CGRP）单克隆抗体（mAbs）已成为针对偏头痛专门开发的第一类预防性治疗方法。临床试验数据表明，CGRP mAb在预防偏头痛症状，特定于偏头痛的生活质量和与头痛相关的残疾方面优于安慰剂。在整个临床试验中，总体而言，与治疗相关的副作用与安慰剂没有显着差异，并且由于副作用而导致的停药率一直很低，这可能是由于其外周作用模式所致。连同其给药途径和给药频率，与已建立的偏头痛治疗药库相比，这些新型药物可能构成了一种改善。Erenumab是一种完全的人类抗体，并且是通过阻断其受体而作用于CGRP途径的唯一mAb。这是美国食品药品监督管理局（2018年5月）和欧洲药品管理局（2018年7月）批准的CGRP mAb类中的第一类。Erenumab以两种不同的剂量（70 mg和140 mg）存在，并且每月皮下注射一次。这篇综述总结了erenumab的药理特性，临床试验数据，重点是这种治疗在临床实践中的潜在作用。